Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Published:2022-12 Issue:12 Volume:17 Page:1415-1427
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Garassino Marina C.,Mazieres Julien,Reck Martin,Chouaid Christos,Bischoff Helge,Reinmuth Niels,Cove-Smith Laura,Mansy Talal,Cortinovis Diego,Migliorino Maria R.,Delmonte Angelo,Sánchez José Garcia,Chara Velarde Luis Enrique,Bernabe Reyes,Paz-Ares Luis,Perez Ignacio Diaz,Trunova Nataliya,Foroutanpour Kayhan,Faivre-Finn Corinne

Funder

Merck

Pfizer

Novartis

AstraZeneca

Roche

Bristol-Myers Squibb

Celgene

Eli Lilly and Company

Boehringer Ingelheim

GlaxoSmithKline

NIHR Maudsley Biomedical Research Centre

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

2. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

3. Management of stage III non-small-cell lung cancer ASCO guideline;Daly;J Clin Oncol,2022

4. Electronic address: clinicalguidelines@esmo.org. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy;Remon;Ann Oncol,2021

5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS;Park;Ann Oncol,2020

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials;Cancer Treatment Reviews;2024-09

2. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study);Lung Cancer;2024-08

3. Neue radioonkologische Therapiekonzepte beim nicht metastasierten Lungenkarzinom;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2024-08

4. Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia;Meditsinskiy sovet = Medical Council;2024-07-24

5. Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study;Radiotherapy and Oncology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3